Skip to main content
Premium Trial:

Request an Annual Quote

NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation

NEW YORK (GenomeWeb) – Lifecode today announced a previously undisclosed Series A Round in financing that raised $20.5 million. The firm also said it received accreditation from the College of American Pathologists. 

The $20.5 million financing was led by Sequoia Capital, Mayo Clinic, and Mayo Ventures. Based in Foster City, Calif., and previously called Silicon Valley Biosystems, Lifecode was founded two years ago and is developing next-generation sequencing-based cancer assays to detect and interpret genomic alterations in patient tumor samples.

Last month the company launched its Pan Cancer Somatic Panel to select physicians in the US with plans to commercialize it more broadly in the spring. 

Lifecode received CAP accreditation following an inspection of its staff qualifications, equipment, quality controls, safety programs, records, and overall management of clinical laboratories. In June 2013, Lifecode received CLIA certification from the California Department of Public Health.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.